

Cover Story
Conversation with The Cancer LetterFree
After a decade of near-absence from the US market, the AstraZeneca drug Iressa (gefitinib) is back.
In Brief


Drugs & Targets
Trending Stories
- Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- Lawsuits brought against Tempus AI raise more questions than answers about DNA privacy in the AI era
- Vinay Prasad, oncologist and Twitter star, locked in debate over precision medicine
- GRAIL presses on with Galleri test despite missed primary endpoint in pivotal study
Where GRAIL sees signals of benefit in the subgroups, screening experts see signs of overdiagnosis - Two lawsuits vs. Tempus raise questions about privacy of germline data in cancer RWE
“Deidentified” ≠ “deidentifiable” - Kim Rathmell named OSUCCC director, Pollock becomes director emeritus in planned leadership transition











